Dec 31, 2015
Group 1 PAH: Current Therapies
Group 4 CTEPH
Prostacyclin Pathway: Modulation by Available Agents
SERAPHIN: Primary End Point*
Prostacyclin Pathway: Modulation by Investigational Agents
CTEPH: Lung Tissue Samples Show Distal Arteriopathy
Recent/Ongoing Trials: Address Previously Unmet Needs
Use of Other PAH Therapies
PATENT-1: Hypotension
Angiogenesis and PDGF: Modulation by Tyrosine Kinase
Inhibitors
PATENT-1 and SERAPHIN at ESC
References
References (cont)
References (cont)
Abbreviations
Abbreviations (cont)